Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.

Slides:

Advertisements

Similar presentations

¿Qué ver en ASCO 2017?.

Advertisements

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Phase Ib/II ECHO-202/KEYNOTE-037: Epacadostat + Pembrolizumab in Pts With Advanced Urothelial Carcinoma CCO Independent Conference Highlights* of the 2017.

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Nat. Rev. Clin. Oncol. doi: /nrclinonc

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Discussion Outline Cells of the Immune System.

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Merkel Cell Carcinoma: What Do Clinicians Need to Know?

Introduction to Checkpoint Inhibitors

REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design

Metastatic Renal Cell Carcinoma

Cancer Stem Cell Therapies in Gastrointestinal Cancers

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Updates in Lung Cancer: Insights From Vienna

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Activity Goals. Activity Goals Discussion Topics.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Management of Glioblastoma

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Basics of Immunotherapy Potential Therapeutic Targets.

Treating mRCC After Initial Antiangiogenic Therapy:

Advanced Lung Cancers: What's on the Horizon?

More Than Meets the Eye.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Patient-Centered Management in Pancreatic Cancer

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Advances in Gastrointestinal Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Preparing for Checkpoint Inhibitors in Breast Cancer

Novel Concepts in the Management of RCC

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Activity Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Genitourinary Cancers.

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Going Beyond EXTREME in Head and Neck Cancer

Moving Care Forward in Advanced Gastric Cancer

New Options for the Treatment of Hepatocellular Carcinoma

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View.

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Recent Developments in the Treatment of Advanced and Metastatic RCC

Presentation transcript:

Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers

Program Goals

CheckMate-032 Nivolumab Monotherapy in Advanced/Metastatic GC/GEJ Cancer

CheckMate-032 (cont) Nivolumab Monotherapy in Advanced/Metastatic GC/GEJ Cancer

KEYNOTE-028 Pembrolizumab in Advanced Esophageal Carcinoma

KEYNOTE-028 (cont) Pembrolizumab in Advanced Esophageal Carcinoma

KEYNOTE-059 Pembrolizumab + 5-FU + Cisplatin in Advanced GC

KEYNOTE-059 (cont) Pembrolizumab + 5-FU + Cisplatin in Advanced GC

Avelumab in Advanced Gastric or GEJ Cancer

Avelumab in Advanced Gastric or GEJ Cancer (cont)

Phase 2 Study Nivolumab in Esophageal Cancer

Biomarker of Response

Future Directions GI Cancers

Abbreviations

Abbreviations (cont)